Johnson & Johnson (JNJ) 100.81 $JNJ
Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition (Updated)
M2 - 2 hrs 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/3bnrl3/pharmaceutical) has announced the addition of Supplier Relations US, LLC's new report "Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition" to their offering. This 2014 publication of Pharmaceutical Preparation Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $148.9 billion USD, with an estimated gross profit of 67.29%. Import was valued at $51.1 billion USD from 80 countries. The industry also exported $30.6 billion USD worth of merchandise to 198 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $169.4 billion USD. At 174 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Bristol-Myers Squibb Company - Cargill, Incorporated - Chattem, Inc. - Eli Lilly and Company - Endo Pharmaceuticals Holdings Inc. - Genzyme Corporation - Hospira, Inc. - Johnson & Johnson - Merck & Co. Inc. - Mylan Laboratories, Inc. - NBTY, Inc. - Pfizer Inc. - Sigma-Aldrich Corporation - Teva Pharmaceuticals USA, Inc. - The Perrigo Company - The Procter & Gamble Company For more information visit http://www.researchandmarkets.com/research/3b...maceutical Source: Supplier Relations US, LLC
Final Glance: Pharmaceuticals companies
AP - Tue May 27, 5:09PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 27, 5:09PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Biotech Tweet of the Week: The Best of ASCO Is Yet to Come
Brian Orelli and David Williamson, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On this week's episode of Biotech Banter , senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing:...
Johnson & Johnson Focusing on Quality Over Quantity
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On May 22, Johnson & Johnson hosted an all-day analyst day for its medical device business. This meeting didn't really offer any major surprises, but did highlight management's intention to run this business with a focus on returns and scale...
Midday Glance: Pharmaceuticals companies
AP - Tue May 27, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue May 27, 12:27PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
EU Nod for Eli Lilly/Boehringer's Jardiance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 10:50AM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim's Jardiance (empagliflozin) is approved by the FDA for type II diabetes.
Early Glance: Pharmaceuticals companies
AP - Tue May 27, 9:24AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue May 27, 9:24AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
U.S. Vascular Device Market Report 2014 - Executive Summary
M2 - Tue May 27, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vlp3v/u_s_vascular) has announced the addition of the "U.S. Vascular Device Market 2014 (Executive Summary)" report to their offering. The U.S. Vascular Access Market was valued at $3.7 billion in 2013 and is expected to grow to over $5 billion by 2020 This growth is fueled by government safety and reimbursement policies created to reduce infection and injury rates. As a result, hospitals are taking steps to reduce injuries by increasing the use of safety products such as pivoting needles, shield safety products retractable syringes and catheter securement technologies. The rise in demand for vascular access devices is proportional to the addressable patient population including oncology, ICU and diabetic patients. In 2013, approximately 90% of patients who were hospitalized in the U.S. received some sort of vascular access treatment during their stay, including the use of IV catheters and syringes. One of the strongest segments driving the vascular access market is the catheter securement market, which is expected to experience double digit growth by 2020. This segment includes Ultrasound and Tip-Location technologies, Peripheral Intravenous Catheters, Dialysis Catheters and Central Venous Catheters (CVCs). Leading the market for vascular access market is Becton Dickinson (BD), despite participating in only two market segments, the PIVC and syringe & needle markets. Other major competitors in the U.S. market includes C.R. Bard, Covidien, Teleflex Medical, Johnson & Johnson and Smith & Nephew. This report includes the latest data, market analyses and competitor profiles. This market segment includes the implantable port, port needle, central venous catheter, peripherally inserted central catheter, peripheral intravenous catheter, dialysis catheter, ultrasound vascular access device and accessories, catheter securement device, syringe and needle market. Key Topics Covered: - U.S. Vascular Access Device Market - Implantable Port Market - Central Venous Catheter Market - Peripherally Inserted Central Catheter Market - Peripheral Intravenous Catheter Market - Dialysis Catheter Market - Ultrasound Vascular Access Device And Accessories Market - Catheter Securement Device Market - Syringe And Needle Market - Competitive Analysis Companies Mentioned - AngioDynamics - B. Braun - Becton Dickinson - C. R. Bard - Covidien - GE Healthcare - Medcomp - Smiths Medical - SonoSite - Teleflex Medical - Terumo Medical For more information visit http://www.researchandmarkets.com/research/9v...s_vascular
Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - Tue May 27, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial
The Dow's Top 3 Stocks of 2014
Travis Hoium, The Motley Fool - Motley Fool - Mon May 26, 5:03PM CDT
After a banner year in 2013, this year has been less remarkable for the Dow Jones Industrial Average and the stock market in general. Last year's market was driven by multiple expansion, not earnings growth, and earnings now are just trying to...
Cardiovascular Devices - Growth Opportunities In Emerging Markets
M2 - Mon May 26, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94l67n/cardiovascular) has announced the addition of the "Cardiovascular Devices - Growth Opportunities In Emerging Markets" report to their offering. A timely and unique growth opportunity exists for cardiovascular device manufacturers seeking to offset some of the tepid or declining growth they have been experiencing in the US and Western European markets. As a result, multinational cardiovascular device companies have been increasing their investments in emerging nations - and they are reaping the rewards, with demand for some cardiovascular devices increasing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey. Combined, these five emerging countries performed an estimated 2.2 million cardiovascular procedures in 2013 - including interventional cardiology procedures, cardiothoracic surgeries (eg, CABG surgery, heart valve procedures, congenital heart disease procedures, and procedures for aortic aneurysms), and cardiac rhythm management procedures (eg, pacemaker/defibrillator implantations and cardiac ablations) - and that number is projected to increase to more than 3.5 million by 2017, a compound annual growth rate of about 13%. China alone is responsible for nearly 60% of that total (about 1.3 million procedures in 2013) and also offers the highest growth rate of the five over the forecast period (16.8%). This dynamic, new report offers a detailed look at the most promising future growth opportunities for cardiovascular device companies in the BRIC nations and Turkey. Included are analyses and comparisons of cardiovascular procedure volumes, growth rates, and market drivers/limiters for each country covered. The report also provides an overview of multinational cardiovascular device company strategies for penetrating these markets as well as an assessment of next-generation technologies, including "leadless" pacemakers and defibrillators and bioresorbable coronary stents, and their potential to further expand growth in emerging market regions. Key Topics Covered: - Market Overview - Coronary Revascularization - Cardiac Rhythm Management Procedures - Heart Valve Procedures - Cardiovascular Device Opportunities In Emerging Markets, By Country - Multinationals Look To Emerging Markets For Growth - Impact Of New Technologies In Emerging Markets Companies Mentioned - Abbott Laboratories - Abbott Vascular - Apollo Hospitals Enterprise Ltd. - Biosense Webster/Johnson & Johnson - Biostar - Boston Scientific - China Kanghui Holdings - Covidien - Edwards Lifesciences - GE Healthcare - LifeTech Scientific Corp. - Medicall Biomedikal AS - Medtronic - Philips Medical - St. Jude Medical - Stryker - Terumo For more information visit http://www.researchandmarkets.com/research/94...iovascular
Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...
Global Coronary Stents (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) Market Report 2014-2019
M2 - Mon May 26, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dp3jcc/coronary_stents) has announced the addition of the "Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report studies the current as well as future prospects of the coronary stents market globally. The market for coronary stents is categorized into three major segments, namely, bare metal stents (BMS), drug eluting stents (DES) and bio-absorbable stents. Each of the market segments has been extensively analyzed on the basis of their commercial existence, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each product type has been provided for the period 2011 to 2019. The report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year. The global coronary stents market has been categorized into four geographical regions - North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market sizes and forecasts for each of these regions have been provided for the period 2011 to 2019 along with CAGR (%) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global coronary stents market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter's five forces analysis and key players' market share analysis in 2012 for the global coronary stents market. A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report also comprises a section on pipeline overview for this market that includes qualitative analysis for various coronary stents currently under phase II, III & IV clinical trials, which are expected to be launched during the forecast period. The global coronary stents market is segmented as follows: Coronary Stents Market, by Product Type - Bare Metal Stents - Drug Eluting Stents - Bio-absorbable Stents Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Coronary Stents Market Overview Chapter 4 Global Coronary Stents Market, by Product Type Chapter 5 Global Coronary Stents Market: Pipeline Overview Chapter 6 Global Coronary Stents Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - amg International GmbH - B. Braun Melsungen AG - Biotronik SE & Co. KG - Boston Scientific Corporation - C. R. Bard, Inc. - Cook Medical, Inc. - Johnson & Johnson - Medtronic, Inc. - MicroPort Scientific Corporation - STENTYS SA - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/dp...ary_stents
Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global
3 Breakthrough Drugs Yield 1 Instant Blockbuster
Todd Campbell, The Motley Fool - Motley Fool - Sat May 24, 10:43AM CDT
The FDA approved 27 new drugs in 2013, including three drugs that were approved under the FDA's breakthrough therapy pathway. That pathway was established by the FDA to speed up clinical trials and FDA approval timelines in a bid to get promising new...
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition (Updated)
M2 - 2 hrs 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/3bnrl3/pharmaceutical) has announced the addition of Supplier Relations US, LLC's new report "Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition" to their offering. This 2014 publication of Pharmaceutical Preparation Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $148.9 billion USD, with an estimated gross profit of 67.29%. Import was valued at $51.1 billion USD from 80 countries. The industry also exported $30.6 billion USD worth of merchandise to 198 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $169.4 billion USD. At 174 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Bristol-Myers Squibb Company - Cargill, Incorporated - Chattem, Inc. - Eli Lilly and Company - Endo Pharmaceuticals Holdings Inc. - Genzyme Corporation - Hospira, Inc. - Johnson & Johnson - Merck & Co. Inc. - Mylan Laboratories, Inc. - NBTY, Inc. - Pfizer Inc. - Sigma-Aldrich Corporation - Teva Pharmaceuticals USA, Inc. - The Perrigo Company - The Procter & Gamble Company For more information visit http://www.researchandmarkets.com/research/3b...maceutical Source: Supplier Relations US, LLC
Final Glance: Pharmaceuticals companies
AP - Tue May 27, 5:09PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 27, 5:09PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Biotech Tweet of the Week: The Best of ASCO Is Yet to Come
Brian Orelli and David Williamson, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On this week's episode of Biotech Banter , senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing:...
Johnson & Johnson Focusing on Quality Over Quantity
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On May 22, Johnson & Johnson hosted an all-day analyst day for its medical device business. This meeting didn't really offer any major surprises, but did highlight management's intention to run this business with a focus on returns and scale...
Midday Glance: Pharmaceuticals companies
AP - Tue May 27, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue May 27, 12:27PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
EU Nod for Eli Lilly/Boehringer's Jardiance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 10:50AM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim's Jardiance (empagliflozin) is approved by the FDA for type II diabetes.
Early Glance: Pharmaceuticals companies
AP - Tue May 27, 9:24AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue May 27, 9:24AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
U.S. Vascular Device Market Report 2014 - Executive Summary
M2 - Tue May 27, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vlp3v/u_s_vascular) has announced the addition of the "U.S. Vascular Device Market 2014 (Executive Summary)" report to their offering. The U.S. Vascular Access Market was valued at $3.7 billion in 2013 and is expected to grow to over $5 billion by 2020 This growth is fueled by government safety and reimbursement policies created to reduce infection and injury rates. As a result, hospitals are taking steps to reduce injuries by increasing the use of safety products such as pivoting needles, shield safety products retractable syringes and catheter securement technologies. The rise in demand for vascular access devices is proportional to the addressable patient population including oncology, ICU and diabetic patients. In 2013, approximately 90% of patients who were hospitalized in the U.S. received some sort of vascular access treatment during their stay, including the use of IV catheters and syringes. One of the strongest segments driving the vascular access market is the catheter securement market, which is expected to experience double digit growth by 2020. This segment includes Ultrasound and Tip-Location technologies, Peripheral Intravenous Catheters, Dialysis Catheters and Central Venous Catheters (CVCs). Leading the market for vascular access market is Becton Dickinson (BD), despite participating in only two market segments, the PIVC and syringe & needle markets. Other major competitors in the U.S. market includes C.R. Bard, Covidien, Teleflex Medical, Johnson & Johnson and Smith & Nephew. This report includes the latest data, market analyses and competitor profiles. This market segment includes the implantable port, port needle, central venous catheter, peripherally inserted central catheter, peripheral intravenous catheter, dialysis catheter, ultrasound vascular access device and accessories, catheter securement device, syringe and needle market. Key Topics Covered: - U.S. Vascular Access Device Market - Implantable Port Market - Central Venous Catheter Market - Peripherally Inserted Central Catheter Market - Peripheral Intravenous Catheter Market - Dialysis Catheter Market - Ultrasound Vascular Access Device And Accessories Market - Catheter Securement Device Market - Syringe And Needle Market - Competitive Analysis Companies Mentioned - AngioDynamics - B. Braun - Becton Dickinson - C. R. Bard - Covidien - GE Healthcare - Medcomp - Smiths Medical - SonoSite - Teleflex Medical - Terumo Medical For more information visit http://www.researchandmarkets.com/research/9v...s_vascular
Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - Tue May 27, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial
The Dow's Top 3 Stocks of 2014
Travis Hoium, The Motley Fool - Motley Fool - Mon May 26, 5:03PM CDT
After a banner year in 2013, this year has been less remarkable for the Dow Jones Industrial Average and the stock market in general. Last year's market was driven by multiple expansion, not earnings growth, and earnings now are just trying to...
Cardiovascular Devices - Growth Opportunities In Emerging Markets
M2 - Mon May 26, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94l67n/cardiovascular) has announced the addition of the "Cardiovascular Devices - Growth Opportunities In Emerging Markets" report to their offering. A timely and unique growth opportunity exists for cardiovascular device manufacturers seeking to offset some of the tepid or declining growth they have been experiencing in the US and Western European markets. As a result, multinational cardiovascular device companies have been increasing their investments in emerging nations - and they are reaping the rewards, with demand for some cardiovascular devices increasing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey. Combined, these five emerging countries performed an estimated 2.2 million cardiovascular procedures in 2013 - including interventional cardiology procedures, cardiothoracic surgeries (eg, CABG surgery, heart valve procedures, congenital heart disease procedures, and procedures for aortic aneurysms), and cardiac rhythm management procedures (eg, pacemaker/defibrillator implantations and cardiac ablations) - and that number is projected to increase to more than 3.5 million by 2017, a compound annual growth rate of about 13%. China alone is responsible for nearly 60% of that total (about 1.3 million procedures in 2013) and also offers the highest growth rate of the five over the forecast period (16.8%). This dynamic, new report offers a detailed look at the most promising future growth opportunities for cardiovascular device companies in the BRIC nations and Turkey. Included are analyses and comparisons of cardiovascular procedure volumes, growth rates, and market drivers/limiters for each country covered. The report also provides an overview of multinational cardiovascular device company strategies for penetrating these markets as well as an assessment of next-generation technologies, including "leadless" pacemakers and defibrillators and bioresorbable coronary stents, and their potential to further expand growth in emerging market regions. Key Topics Covered: - Market Overview - Coronary Revascularization - Cardiac Rhythm Management Procedures - Heart Valve Procedures - Cardiovascular Device Opportunities In Emerging Markets, By Country - Multinationals Look To Emerging Markets For Growth - Impact Of New Technologies In Emerging Markets Companies Mentioned - Abbott Laboratories - Abbott Vascular - Apollo Hospitals Enterprise Ltd. - Biosense Webster/Johnson & Johnson - Biostar - Boston Scientific - China Kanghui Holdings - Covidien - Edwards Lifesciences - GE Healthcare - LifeTech Scientific Corp. - Medicall Biomedikal AS - Medtronic - Philips Medical - St. Jude Medical - Stryker - Terumo For more information visit http://www.researchandmarkets.com/research/94...iovascular
Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...
Global Coronary Stents (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) Market Report 2014-2019
M2 - Mon May 26, 8:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dp3jcc/coronary_stents) has announced the addition of the "Coronary Stents Market - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report studies the current as well as future prospects of the coronary stents market globally. The market for coronary stents is categorized into three major segments, namely, bare metal stents (BMS), drug eluting stents (DES) and bio-absorbable stents. Each of the market segments has been extensively analyzed on the basis of their commercial existence, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each product type has been provided for the period 2011 to 2019. The report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year. The global coronary stents market has been categorized into four geographical regions - North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market sizes and forecasts for each of these regions have been provided for the period 2011 to 2019 along with CAGR (%) for the forecast period 2013 to 2019. The research study also incorporates the competitive scenario in these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the global coronary stents market and future opportunities has been provided in the market overview section. This section of the report also deals with market attractiveness analysis, Porter's five forces analysis and key players' market share analysis in 2012 for the global coronary stents market. A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report also comprises a section on pipeline overview for this market that includes qualitative analysis for various coronary stents currently under phase II, III & IV clinical trials, which are expected to be launched during the forecast period. The global coronary stents market is segmented as follows: Coronary Stents Market, by Product Type - Bare Metal Stents - Drug Eluting Stents - Bio-absorbable Stents Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Coronary Stents Market Overview Chapter 4 Global Coronary Stents Market, by Product Type Chapter 5 Global Coronary Stents Market: Pipeline Overview Chapter 6 Global Coronary Stents Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - amg International GmbH - B. Braun Melsungen AG - Biotronik SE & Co. KG - Boston Scientific Corporation - C. R. Bard, Inc. - Cook Medical, Inc. - Johnson & Johnson - Medtronic, Inc. - MicroPort Scientific Corporation - STENTYS SA - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/dp...ary_stents
Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global
3 Breakthrough Drugs Yield 1 Instant Blockbuster
Todd Campbell, The Motley Fool - Motley Fool - Sat May 24, 10:43AM CDT
The FDA approved 27 new drugs in 2013, including three drugs that were approved under the FDA's breakthrough therapy pathway. That pathway was established by the FDA to speed up clinical trials and FDA approval timelines in a bid to get promising new...
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
